{
    "id": "5b196b1f-408e-4615-b980-9f822adff835",
    "indications": {
        "text": "dabigatran etexilate capsules direct thrombin inhibitor indicated : reduce risk stroke systemic embolism adult patients non-valvular atrial fibrillation ( 1.1 ) treatment deep venous thrombosis ( dvt ) pulmonary embolism ( pe ) adult patients treated parenteral anticoagulant 5 10 days ( 1.2 ) reduce risk recurrence dvt pe adult patients previously treated ( 1.3 ) prophylaxis dvt pe adult patients undergone hip replacement surgery ( 1.4 ) treatment venous thromboembolic events ( vte ) pediatric patients 8 less 18 years age treated parenteral anticoagulant least 5 days ( 1.5 ) reduce risk recurrence vte pediatric patients 8 less 18 years age previously treated ( 1.6 )",
        "doid_entities": [
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            },
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "pulmonary embolism (DOID:9477)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9477"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "non-valvular atrial fibrillation adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily ( 2.2 ) patients crcl 15 30 ml/min : 75 mg orally , twice daily ( 2.2 ) treatment dvt pe adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily 5 10 days parenteral anticoagulation ( 2.2 ) reduction risk recurrence dvt pe adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily previous treatment ( 2.2 ) prophylaxis dvt pe following hip replacement surgery adult patients : patients crcl > 30 ml/min : 110 mg orally first day , 220 mg daily ( 2.2 ) treatment pediatric vte : pediatric patients : weight-based , twice daily least 5 days parenteral anticoagulant ( 2.3 ) reduction risk recurrence pediatric vte : pediatric patients : weight-based , twice daily previous treatment ( 2.3 ) dabigatran etexilate capsules substitutable milligram-to-milligram basis dabigatran etexilate forms review recommendations converting oral parenteral anticoagulants ( 2.6 , 2.7 ) temporarily discontinue dabigatran etexilate capsules invasive surgical procedures possible , restart promptly ( 2.8 )",
        "doid_entities": [
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "invasive surgical procedures",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_90080"
            }
        ]
    },
    "warningsAndPrecautions": "dabigatran etexilate capsules 75 mg cellulose capsule size \u201c 2 \u201d cream opaque cap imprinted dab cream opaque body imprinted 75 using black ink , containing two off-white pale yellow , round , biconvex , coated tablets white off- white blend . unit bottle 60 capsules ndc 59651-973-60 blister package containing 60 capsules ( 10 x 6 capsule blister cards ) ndc 59651-973-61 dabigatran etexilate capsules 110 mg cellulose capsule size \u201c 1 \u201d blue opaque cap imprinted dab cream opaque body imprinted 110 using black ink , containing three off-white pale yellow , round shaped , biconvex , coated tablets debossed \u201c \u201d one side plain side tablets white off-white blend . unit bottle 60 capsules ndc 59651-974-60 blister package containing 60 capsules ( 10 x 6 capsule blister cards ) ndc 59651-974-61 dabigatran etexilate capsules 150 mg cellulose capsule size \u201c 0 \u201d blue opaque cap imprinted dab cream opaque body imprinted 150 using black ink , containing four off-white pale yellow , round , biconvex , coated tablets white off- white blend . unit bottle 60 capsules ndc 59651-975-60 blister package containing 60 capsules ( 10 x 6 capsule blister cards ) ndc 59651-975-61 bottles store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . opened , product must used within 4 months . keep bottle tightly closed . store original package protect moisture . blisters store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . store original package protect moisture .",
    "adverseReactions": "dabigatran etexilate capsules contraindicated patients : active pathological bleeding [ ( 5.2 ) ( 6.1 ) ] history serious hypersensitivity reaction dabigatran , dabigatran etexilate , one excipients product ( e.g . , anaphylactic reaction anaphylactic shock ) [ ( 6.1 ) ] mechanical prosthetic heart valve [ ( 5.4 ) ]",
    "ingredients": [
        {
            "name": "DABIGATRAN ETEXILATE MESYLATE",
            "code": "SC7NUW5IIT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70752"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ETHYLCELLULOSE (10 MPA.S)",
            "code": "3DYK7UYZ62",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)",
            "code": "NZ94SDL6WR"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "CARRAGEENAN",
            "code": "5C69YCD2YJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3435"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POTASSIUM CHLORIDE",
            "code": "660YQ98I10",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32588"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "organization": "Aurobindo Pharma Limited",
    "name": "DABIGATRAN ETEXILATE",
    "effectiveTime": "20250515",
    "indications_original": "Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 )",
    "contraindications_original": "Non-valvular Atrial Fibrillation in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily ( 2.2 ) For patients with CrCl 15 \u00a0to 30 mL/min: 75 mg orally, twice daily ( 2.2 ) Treatment of DVT and PE in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after 5 to 10 days of parenteral anticoagulation ( 2.2 ) Reduction in the Risk of Recurrence of DVT and PE in Adult Patients: For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after previous treatment ( 2.2 ) Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients: For patients with CrCl > 30 mL/min: 110 mg orally first day, then 220 mg once daily ( 2.2 ) Treatment of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after at least 5 days of parenteral anticoagulant ( 2.3 ) Reduction in the Risk of Recurrence of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after previous treatment ( 2.3 ) Dabigatran etexilate capsules are NOT substitutable on a milligram-to-milligram basis with other dabigatran etexilate dosage forms Review recommendations for converting to or from other oral or parenteral anticoagulants ( 2.6 , 2.7 ) Temporarily discontinue dabigatran etexilate capsules before invasive or surgical procedures when possible, then restart promptly ( 2.8 )",
    "warningsAndPrecautions_original": "Dabigatran Etexilate Capsules 75 mg are cellulose capsule of size \u201c2\u201d with cream opaque cap imprinted with DAB and cream opaque body imprinted with 75 using black ink, containing two off-white to pale yellow, round, biconvex, coated tablets and white to off- white blend.\u00a0\u00a0\u00a0 \n                  \n                  Unit of use bottle of 60 capsules \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-973-60\n                  Blister package containing 60 capsules (10 x 6 capsule blister cards)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-973-61\n                  \n                  \n                     Dabigatran Etexilate Capsules 110 mg are cellulose capsule of size \u201c1\u201d with blue opaque cap imprinted with DAB and cream opaque body imprinted with 110 using black ink, containing three off-white to pale yellow, round shaped, biconvex, coated tablets debossed with \u201cD\u201d on one side and plain on the other side of tablets and white to off-white blend.\n                  \n                  Unit of use bottle of 60 capsules \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-974-60\n                  Blister package containing 60 capsules (10 x 6 capsule blister cards)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-974-61\n                  \n                  \n                     Dabigatran Etexilate Capsules 150 mg are cellulose capsule of size \u201c0\u201d with blue opaque cap imprinted with DAB and cream opaque body imprinted with 150 using black ink, containing four off-white to pale yellow, round, biconvex, coated tablets and white to off- white blend.\n                  \n                  Unit of use bottle of 60 capsules \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-975-60\n                  Blister package containing 60 capsules (10 x 6 capsule blister cards)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-975-61\n                  \n                  \n                     \n                        Bottles\n                     \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Once opened, the product must be used within 4 months. Keep the bottle tightly closed. Store in the original package to protect from moisture.\n                  \n                  \n                     \n                        Blisters \n                     \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Store in the original package to protect from moisture.",
    "adverseReactions_original": "Dabigatran etexilate capsules are contraindicated in patients with:\n                  \n                  \n                     Active pathological bleeding [see\u00a0Warnings and Precautions (5.2) and Adverse Reactions (6.1)]\n                     \n                     History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions (6.1)]\n                     \n                     Mechanical prosthetic heart valve [see Warnings and Precautions (5.4)]",
    "drug": [
        {
            "name": "DABIGATRAN ETEXILATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70746"
        }
    ]
}